| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2023-02-19 |
| タイトル |
|
|
タイトル |
Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
axitinib |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
metastatic renal cell carcinoma |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
nivolumab |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 作成者 |
Numakura, Kazuyuki
Muto, Yumin
Naito, Sei
Hatakeyama, Shingo
Kato, Renpei
Koguchi, Tomoyuki
Kojima, Takahiro
Kawasaki, Yoshihide
Kandori, Syuya
Kawamura, Sadafumi
Arai, Yoichi
Ito, Akihiro
Nishiyama, Hiroyuki
Kojima, Yoshiyuki
Obara, Wataru
Ohyama, Chikara
Tsuchiya, Norihiko
Habuchi, Tomonori
|
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Although combination immune checkpoint inhibitor (immuno-oncology [IO]) therapy is the first-line treatment for metastatic renal cell carcinoma (mRCC), it mostly causes resistance and tumor regrowth. Therefore, an optimal second-line therapy is necessary. Such therapy typically comprises vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs). This study was aimed at comparing the efficacy of two TKIs-axitinib and sunitinib-in mRCC patients. From January 2008 to October 2018, we registered 703 mRCC patients from 8 Japanese institutes. Of these, 408 patients received axitinib or sunitinib as the first-line treatment. Thereafter, efficacy and survival rate were compared between the axitinib and sunitinib groups. To reduce the effects of selection bias and potential confounders, propensity score matching analysis was performed. Axitinib and sunitinib were administered in 274 and 134 patients, respectively. More than 25% of the patients received nivolumab sequence therapy. To calculate the propensity scores for each patient, we performed multivariate logistic regression analysis. The objective response rate, progression-free survival (PFS), cause-specific survival, and overall survival (OS) were significantly better in the axitinib group than in the sunitinib group. Furthermore, the OS was better in the nivolumab-treated patients in the axitinib group. Axitinib showed higher efficacy and afforded greater survival benefits than did sunitinib when administered as first-line therapy in mRCC patients. Thus, from among VEGFR-TKIs, axitinib might be a possible option for application in the middle of IO drug-based treatment sequences. |
|
言語 |
en |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 書誌情報 |
en : Cancer Medicine
巻 10,
号 17,
p. 5839-5846,
発行日 2021
|
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
2045-7634 |
| 出版者 |
|
|
出版者 |
John Wiley and Sons Inc |
| 関連情報 |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1002/cam4.4130 |
| 権利情報 |
|
|
権利情報 |
This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. |
iA_2022_35.pdf (469.5 kB)
